Terrific company, great products. Consistent results. Baffling share price (but with low volumes)
Staff costs are too high but presumably a large part is the sales force to drive further growth. It appears that there are up to 150 sales reps who probably cost $20M (NZD) . Hopefully this investment delivers top line growth, else perhaps better to trim the sales team and other staff and improve profitability and start getting measured in Growth, P/E and Cash terms which probably will uplift share price in this environment.
News: ARX Aroa Biosurgery Says FY24 Product Revenue Guidance Maintained At NZ$72-75 Mln, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
0.005(0.96%) |
Mkt cap ! $181.0M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 52.5¢ | 51.0¢ | $148.1K | 289.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 42081 | 3 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| ARX (ASX) Chart |